Anthropic launches its own drug discovery program for neglected diseases

Anthropic on Tuesday unveiled Claude Science, an AI research workbench for scientists, while simultaneously announcing it will pursue its own preclinical drug discovery programs targeting neglected diseases — areas that traditional pharmaceutical companies have historically avoided.

The announcement marks an unusual move for an AI company: not merely selling tools to drugmakers, but doing the drug discovery work itself.

A New Kind of AI Company in Pharma

"These are areas that are outside the scope of what the traditional pharma and biotech landscape might consider attractive targets, but nonetheless have real burden associated with them," Eric Kauderer-Abrams, Anthropic's head of life sciences, said during a press briefing on Tuesday.reuters+1

The preclinical programs represent the culmination of a year-long push by Anthropic into biology. Since hiring Kauderer-Abrams in August 2025, the company has launched Claude for Life Sciences, acquired drug discovery startup Coefficient Bio for roughly $400 million, opened wet labs to conduct its own basic research, and hired Jonah Cool, formerly of the Chan Zuckerberg Initiative, to lead life sciences partnerships.synbiobeta+5

Claude Science itself combines more than 60 scientific databases, coding tools, and computing workflows in a single workspace. It can render 3D protein structures, genome browser tracks, and chemistry drawings, and allows researchers to trace results back to their source code.channelnewsasia

Bridging Tool Sales and Internal Research

The neglected diseases initiative is designed to complement rather than compete with Anthropic's pharmaceutical customers. The company is courting major drugmakers to adopt Claude Science, and positioning its internal work on diseases those firms would not pursue as evidence of its technology's capabilities.

Kauderer-Abrams told STAT News that he considers biology "the single most important thing" at Anthropic and expects Claude Science to transform the life sciences the way Claude Code changed computer programming. At SynBioBeta in May, he described Anthropic's goal of compressing the drug development timeline by a factor of ten.statnews+1

The Financial Firepower Behind the Bet

Anthropic's ambitions are backed by extraordinary resources. The company recently reported annualized revenue of $42 billion and is valued at $965 billion based on a $65 billion funding round, according to STAT News — making it worth more than any health care company except Eli Lilly ↗ 0.61%. The company held a live event Tuesday in San Francisco, "The Briefing: AI for Science," featuring leadership and life sciences executives.anthropic+1

No FDA-approved drug has yet emerged from the roughly $60 billion invested in AI-driven drug discovery since 2019, though about 175 AI-originated programs have entered human trials. Whether Anthropic's combination of financial heft, wet-lab infrastructure, and foundation models can change that equation for diseases the rest of the industry has left behind remains to be seen.medcitynews